Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly



Status:Completed
Conditions:Skin Cancer, Endocrine
Therapuetic Areas:Endocrinology, Oncology
Healthy:No
Age Range:18 - Any
Updated:1/17/2019
Start Date:May 2000
End Date:January 2003

Use our guide to learn which trials are right for you!

Phase II, Multicentre, Randomized, Double-blind Study in Acromegalic Patients Evaluating the Efficacy and Safety of a Single Deep Subcutaneous Administration of Lanreotide Autogel (60, 90 or 120mg) Versus Placebo Followed by a Single Blind Fixed Dose Phase Evaluating the Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Profile of Multiple Deep Subcutaneous Administrations of Lanreotide Autogel (60, 90 & 120mg) Ending in Open Label Dose Titration Phase.

The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo
after a single injection. Effectiveness and safety were then also assessed following four
fixed-dose injections and after one year of treatment given at titrated doses.


Inclusion Criteria:

- documentation of a diagnosis of active acromegaly based on either of the following
definitions:

1. the patient has never received somatostatin analog nor dopaminergic agonist or
had previously received this medication but had stopped more than 3 months before
visit 1 and had a mean growth hormone (GH)level >5ng/mL at visit 1; or

2. the patient was receiving treatment with a somatostatin analog (other than
lanreotide autogel) or a dopaminergic agonist at visit 1, had a mean GH >3ng/mL
at visit 2 (or visit 2a) and had at least a 100% increase in mean GH levels
between visit 1 and visit 2 (or visit 2a)

Exclusion Criteria:

- receipt of radiotherapy for acromegaly within 3 years

- pituitary surgery within 3 months prior to visit 1

- prior receipt of lanreotide autogel or GH antagonist

- anticipated need for pituitary surgery (adenomectomy) or radiotherapy during the study
period

- known hypersensitivity to any of the test materials or related compounds

- clinically significant renal or hepatic abnormalities
We found this trial at
12
sites
Chicago, Illinois 60611
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
161
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
733 North Broadway
Baltimore, Maryland 21205
(410) 955-3182
Johns Hopkins University School of Medicine Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is...
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Birmingham, Alabama 35213
491
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
?
mi
from 43215
Brno,
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Houston, Texas 77030
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90048
1978
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
New York, New York 10021
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Portland, Oregon 97227
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials